Arrowhead Pharmaceuticals Hosts R&D Day on Emerging Pipeline of Pulmonary Targeted RNAi Therapeutics

Arrowhead Pharmaceuticals Hosts R&D Day on Emerging Pipeline of Pulmonary Targeted RNAi Therapeutics

May 26, 2022 by Business Wire Health News

Key Facts

  • Arrowhead will describe the development of investigational candidates: ARO-MUC5AC, designed to reduce expression of mucin 5AC (MUC5AC) as a potential treatment for various muco-obstructive pulmonary diseases ARO-RAGE, designed to reduce expression of the receptor for advanced glycation end products (RAGE) as a potential treatment for various obstructive inflammatory pulmonary diseases * ARO-MMP7, Arrowhead’s newest and previously undisclosed candidate designed to the reduce expression of matrix metalloproteinase 7 (MMP7) as a potential treatment for idiopathic pulmonary fibrosis (IPF) The company will also discuss learnings from its first pulmonary clinical candidate, ARO-ENaC, that led to enhanced candidate and platform designs that have the potential to offer improved potency, duration, and the flexibility of subcutaneous as well as inhaled delivery.
  • In a rat model of allergic asthma, silencing RAGE in the lung effectively reduced inflammatory cell recruitment and cytokines , supporting the rationale for targeting RAGE in inflammatory lung disease.
  • In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements.
  • Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the impact of the ongoing COVID-19 pandemic on our business, the safety and efficacy of our product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time.

Click To Read Full Article


This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at Write to © 2021 Kwhen Inc.

Was this content valuable for you?